We are live on ! Find out more
PAP

Persistent Asset Partners Portfolio holdings

AUM $268M
1-Year Est. Return 158.98%
This Fund
S&P 500
This Quarter Est. Return
+11.27%
1 Year Est. Return
+158.98%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$135M
AUM Growth
+$15.6M
Cap. Flow
+$220M
Cap. Flow %
163.5%
Top 10 Hldgs %
31.52%
Holding
253
New
80
Increased
47
Reduced
36
Closed
74

Top Buys

1
HUM icon
Humana
HUM
+$4.21M
2
AMGN icon
Amgen
AMGN
+$3.4M
3
EHC icon
Encompass Health
EHC
+$3.34M
4
SLNO
Soleno Therapeutics
SLNO
+$3.29M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$1.9M

Top Sells

1
CNC icon
Centene
CNC
+$10.3M
2
UNH icon
UnitedHealth
UNH
+$4.9M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$3.17M
4
IBIT icon
iShares Bitcoin Trust
IBIT
+$3M
5
CON
Concentra Group Holdings
CON
+$2.39M

Sector Composition

1 Healthcare 51.79%
2 Financials 16.59%
3 Materials 5%
4 Technology 2.34%
5 Energy 1.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OLMA icon
101
Olema Pharmaceuticals
OLMA
$1B
$248K 0.18%
58,333
+35,345
+154% +$158K
SPRY icon
102
CALL
ARS Pharmaceuticals
SPRY
$695M
$248K 0.18%
+646
New +$9.32K
RVPH
103
DELISTED
REVIVA PHARMA HLDGS INC
RVPH
$244K 0.18%
32,059
+24,043
+300% +$374K
MREO
104
CALL
Mereo BioPharma
MREO
$49.5M
$244K 0.18%
3,035
+1,849
+156% +$4.46K
OBT icon
105
Orange County Bancorp
OBT
$504M
$243K 0.18%
+9,390
New +$229K
DFTX
106
Definium Therapeutics
DFTX
$5.88B
$238K 0.18%
+36,642
New +$241K
TRVI icon
107
Trevi Therapeutics
TRVI
$2.71B
$234K 0.17%
42,788
+1,384
+3% +$8.61K
INTC icon
108
Intel
INTC
$478B
$224K 0.17%
10,000
– –
COGT icon
109
PUT
Cogent Biosciences
COGT
$6.68B
$223K 0.17%
59,797
+59,318
+12,384% +$329K
TERN
110
DELISTED
Terns Pharmaceuticals
TERN
$223K 0.17%
59,797
+46,990
+367% +$147K
ETNB
111
DELISTED
89bio
ETNB
$222K 0.16%
22,618
-30,606
-58% -$253K
Z icon
112
Zillow
Z
$7.76B
$215K 0.16%
+3,071
New +$207K
VBTX
113
DELISTED
Veritex Holdings
VBTX
$208K 0.15%
+7,980
New +$190K
NBN icon
114
Northeast Bank
NBN
$1.13B
$208K 0.15%
+2,338
New +$200K
SCPH
115
DELISTED
scPharmaceuticals
SCPH
$191K 0.14%
+50,107
New +$156K
SLSR
116
Solaris Resources
SLSR
$1.18B
$186K 0.14%
40,656
-1,156
-3% -$4.69K
SCPH
117
CALL
DELISTED
scPharmaceuticals
SCPH
$183K 0.14%
+1,123
New +$3.49K
CLYM
118
Climb Bio
CLYM
$727M
$180K 0.13%
145,179
-581
-0.4% -$723
FLNA
119
PUT
Filana Therapeutics
FLNA
$51.2M
$174K 0.13%
86,819
+86,795
+361,646% +$154K
VTGN icon
120
VistaGen Therapeutics
VTGN
$9.4M
$174K 0.13%
86,819
-34,832
-29% -$79.1K
ARVN icon
121
Arvinas
ARVN
$517M
$164K 0.12%
+22,233
New +$164K
HOOD icon
122
CALL
Robinhood
HOOD
$89.7B
$163K 0.12%
+403
New +$23.9K
ESQ icon
123
Esquire Financial Holdings
ESQ
$1.06B
$157K 0.12%
1,656
-1,352
-45% -$117K
RARE icon
124
CALL
Ultragenyx Pharmaceutical
RARE
$2.88B
$129K 0.1%
500
+230
+85% +$8.29K
OCUL icon
125
CALL
Ocular Therapeutix
OCUL
$1.96B
$106K 0.08%
313
– –
3 4
5
6 7

Similar funds

VC
VarCov Co Darien, Connecticut $268M AUM
AL
AIP LLC New York $268M AUM 40.4% 1-Year Est. Return
FC
Foursixthree Capital New York $268M AUM 115.24% 1-Year Est. Return
NF
Nvest Financial Portsmouth, New Hampshire $268M AUM 22.87% 1-Year Est. Return
PF
Prosperitas Financial Valencia, California $268M AUM 32.64% 1-Year Est. Return
UI
Untitled Investments New York $269M AUM 11.35% 1-Year Est. Return
SSWM
Strait & Sound Wealth Management San Francisco, California $269M AUM 22.03% 1-Year Est. Return
AC
Applied Capital Little Rock, Arkansas $268M AUM 16.92% 1-Year Est. Return

Persistent Asset Partners's Q2 2025 Portfolio in Review

As of Q2 2025, Persistent Asset Partners held 253 positions worth $135M, up 13% from $119M the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Persistent Asset Partners deployed $220M of net new capital in Q2 2025, opening 80 new positions and adding to 47 existing holdings. Its largest new stake was Amgen: 12,000 shares worth $3.35M.

By sector, the portfolio is most concentrated in Healthcare at 52% of assets, down from 61% a quarter earlier, followed by Financials and Materials.

On the sell side, the largest reduction was Regeneron Pharmaceuticals, an estimated $3.17M trimmed.

  • Persistent Asset Partners's largest Q2 2025 buy was Amgen: 12,000 shares worth $3.35M.
  • Persistent Asset Partners added most to Humana in Q2 2025, an estimated $4.21M increase.
  • Persistent Asset Partners's biggest Q2 2025 reduction was Regeneron Pharmaceuticals, cutting an estimated $3.17M.
  • Persistent Asset Partners fully exited Centene in Q2 2025, selling an estimated $10.3M.
  • Persistent Asset Partners's ten largest holdings make up 32% of its $135M portfolio in Q2 2025.
  • Persistent Asset Partners opened 80 new positions and closed 74 in Q2 2025.
  • Persistent Asset Partners's portfolio value rose 13% quarter-over-quarter to $135M.

Based on Persistent Asset Partners's 13F filing for Q2 2025, filed 11 Aug 2025.